CMS Enters the Octagon, Names 10 Drugs for Price Negotiation

<p><em>Health Affairs</em>' Rob Lott and Chris Fleming discuss Biden administration's announcement regarding the first 10 drugs selected for Medicare price negotiation.</p><p><a href="https://www.healthaffairs.org/private-sector-solutions/research-and-justice-for-all-podcast?utm_medium=podcast&amp;utm_source=this+week">Listen to the Research and Justice For All trailer</a>.</p><p><strong>Related Link:</strong></p><ul> <li><a href="https://www.whitehouse.gov/briefing-room/statements-releases/2023/08/29/fact-sheet-biden-harris-administration-announces-first-ten-drugs-selected-for-medicare-price-negotiation/">Biden-Harris Administration Announces First Ten Drugs Selected for Medicare Price Negotiation</a></li> <li> <a href="https://www.healthaffairs.org/content/forefront/deep-dive-into-takings-clause-challenges-medicare-drug-price-negotiation-program?utm_medium=podcast&amp;utm_source=this+week">A Deep Dive Into Takings Clause Challenges to the Medicare Drug Price Negotiation Program</a> (<em>Health Affairs Forefront</em>)</li> <li> <a href="https://www.healthaffairs.org/content/forefront/medicare-drug-price-negotiations-principles-based-guide-cms?utm_medium=podcast&amp;utm_source=this+week">Medicare Drug Price Negotiations: A Principles-Based Guide for CMS</a> (<em>Health Affairs Forefront</em>)</li> </ul>